Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Keywords

Affiliated Institutions

• Universitair Ziekenhuis Brussel BE
• Elbe Kliniken Stade-Buxtehude DE
• Royal Marsden Hospital GB
• University Hospital Heidelberg DE
• University of California, Los Angeles US
• Huntsman Cancer Institute US
• Hôpital Lyon Sud FR
• Aix-Marseille Université FR
• Yale Cancer Center US
• The Christie Hospital GB
• Technical University of Munich DE
• Roswell Park Comprehensive Cancer Center US
• University of Siena IT
• German Cancer Research Center DE
• Bristol-Myers Squibb (Belgium) BE
• Medical University of Vienna AT
• Bristol-Myers Squibb (United States) US
• Jewish General Hospital CA
• Herlev Hospital DK
• Moffitt Cancer Center US
• University of Michigan US
• Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" IT
• Dana-Farber Cancer Institute US
• McGill University CA
• Hôpital de la Timone FR
• Cornell University US
• Memorial Sloan Kettering Cancer Center US
• Washington University in St. Louis US
• Mayo Clinic in Arizona US
• Heidelberg University DE
• Northern California Melanoma Center US
• Medizinische Hochschule Hannover DE

Related Publications